Safety and efficacy of tivozanib–nivolumab combination in patients with metastatic kidney cancer
In this phase 1b/2 study the researchers looked at a [...]
Safety and efficacy of TiNivo in patients with metastatic kidney cancer
Tivozanib is a drug that blocks the blood supply to [...]
Tivozanib has a better safety profile than other TKIs for the treatment of kidney cancer
A recent literature review and network meta-analysis of phase 2/3 [...]
PARP inhibitors, vaccines and combination therapies for kidney cancer
In this interview with OncLive, professor Sumanta Kumar Pal from [...]
Potential new treatments for kidney cancer discussed at 2019 Kidney Cancer Research Summit
In this interview from the 2019 Kidney Cancer Research Summit [...]
Tivozanib in heavily pre-treated advanced kidney cancer patients
Further data from the TIVO-3 clinical trial comparing tivozanib with [...]
Tivozanib included in new European guidelines for kidney cancer
Tivozanib has been included as a first-line treatment recommendation for advanced renal [...]
ASCO GU 2019: Tivozanib effective for refractory metastatic kidney cancer
The results from the following study were presented at the [...]
Tivozanib expected to be included in European clinical practice guidelines for advanced kidney cancer
Tivozanib is expected to be included as a first-line treatment [...]
First-line tivozanib approved for use in NHS Scotland
We are delighted that the Scottish Medicines Consortium (SMC), which reviews [...]
